Myeloma Maintenance Therapy: How Long and Can I Stop?
A patient guide to 1-drug vs. 2-drug maintenance regimens, managing long-term side effects, and when sustained MRD negativity allows stepping down
Medical Disclaimer: This guide is synthesized from international clinical consensus guidelines and peer-reviewed literature. It is for educational purposes only and does not substitute for professional medical advice. Always consult your oncology team regarding diagnostic and treatment decisions.
💡 The Short Answer
Reaching remission after induction or a stem cell transplant is a major milestone, and maintenance therapy is the shield that keeps that remission intact. Under the latest NCCN (v2.2027) and EHA-EMN (2025) guidelines, continuous maintenance therapy after Autologous Stem Cell Transplant (ASCT) or frontline induction more than doubles median progression-free survival from 23.5 to 52.8 months and cuts death risk by 25%. Standard-risk patients typically take Category 1 single-agent lenalidomide (10 mg daily) or daratumumab plus lenalidomide (Dara-R), whereas high-risk patients require 2-drug maintenance pairing lenalidomide with carfilzomib (FORTE/ATLAS), bortezomib, or daratumumab (PERSEUS/AURIGA). While complete treatment stopping outside clinical trials is not yet standard, patients on 2-drug Dara-R who complete 24 months and achieve Sustained MRD Negativity (10⁻⁵ to 10⁻⁶ for ≥ 12 months) can safely step down to lenalidomide alone, while proactively managing long-term cytopenias, bile-acid diarrhea, and infection protection.
Why This Matters
After months of weekly clinic visits, injections, or recovering from a stem cell transplant, hearing that you still need to take maintenance medication for years can feel discouraging. Understanding three core facts about maintenance therapy helps turn frustration into confidence:
- Maintenance is not "more heavy chemotherapy"—it is a low-dose security patrol: If induction and transplant are the firefighters that put out the blaze, maintenance is the neighborhood patrol that keeps hidden embers from reigniting, using gentle doses (often without steroids) so you can return to work, travel, and family life.
- It adds years to both your remission and your overall lifespan: Landmark studies of more than 1,200 patients proved that maintenance therapy does not just delay relapse on paper—it increases 7-year overall survival from 50% to 62%.
- Nearly every long-term side effect has a simple fix or dose step-down: Whether you experience low white blood counts, leg cramps, fatigue, or chronic loose stools after a year on lenalidomide, simple dose adjustments (10 mg down to 5 mg) or targeted supportive medicines can keep you comfortable.
If you are wrapping up induction or recovering from transplant, see where maintenance fits into your overall treatment roadmap. This guide explains how doctors match 1-drug versus 2-drug maintenance to your risk profile, how long treatment lasts, when Sustained MRD Negativity allows stepping down, and how to manage long-term side effects.
📖 Key Terms in Plain English
| Term | Plain-English Meaning |
|---|---|
| Maintenance Therapy | Low-intensity, long-term therapy started after stem cell transplant (usually around Day +90 to +100) or after initial induction cycles to prevent myeloma from coming back |
| Single-Agent vs. Dual Maintenance | Taking 1 oral drug (lenalidomide alone) for standard-risk myeloma versus pairing 2 drugs (lenalidomide plus daratumumab, carfilzomib, or bortezomib) for high-risk or MRD-positive disease |
| Sustained MRD Negativity | Two or more bone marrow MRD tests (10⁻⁵ or 10⁻⁶ sensitivity) taken at least 12 months apart that both find zero myeloma cells |
| Treatment De-Escalation (Step-Down) | Safely dropping the second maintenance drug (such as stopping monthly daratumumab shots while continuing lenalidomide pills) after proving Sustained MRD Negativity |
| Bile Acid Malabsorption | A very common, reversible cause of watery diarrhea after months of lenalidomide, caused by unabsorbed digestive bile acids irritating the gut |
| Second Primary Malignancy (SPM) | A new, unrelated secondary cancer (most often skin cancer or rare bone marrow changes) that occurs in a small percentage of patients over many years of survivorship |
1. Standard Maintenance Regimens: Matching 1 Drug vs. 2 Drugs to Your Risk
Your hematologist chooses your maintenance regimen based on two main factors: whether your baseline FISH genetics were standard-risk or high-risk, and whether you reached MRD negativity after induction or transplant:
| Maintenance Regimen | Guideline Status & Key Trials | Landmark Efficacy Data | Who Matches This Regimen Best |
|---|---|---|---|
| 1. Single-Agent Lenalidomide (Revlimid Oral Capsules) | NCCN Category 1 Preferred (CALGB 100104, IFM 2005-02, and Myeloma XI Meta-Analysis) | • More than doubles median PFS (52.8 months vs. 23.5 months without maintenance); • Cuts death risk by 25%, extending median Overall Survival by 2.5+ years | • Standard-risk patients after ASCT or induction; • Taken at home (10 mg once daily on Days 1–28, or Days 1–21 of a 28-day cycle; adjusted to 5 mg if kidneys are impaired) |
| 2. Daratumumab + Lenalidomide (Dara-R Dual Maintenance) | NCCN Recommended (PERSEUS and AURIGA Phase 3 Trials) | • PERSEUS: 84.3% 4-year PFS and 64.8% Sustained MRD Negativity; • AURIGA: In post-transplant MRD-positive patients, Dara-R more than doubled MRD-negative conversion at 1 year (50.5% vs. 18.8%) | • Patients who received frontline Dara-VRd; • Post-transplant patients who are still MRD-positive at Day +100; • High-risk patients needing 2-drug protection |
| 3. Carfilzomib + Lenalidomide (KR) or Bortezomib + Len (VR) | NCCN Category 1 Other Recommended / High-Risk Standard (FORTE and ATLAS Trials) | • FORTE & ATLAS: KR dual maintenance raised 3-year PFS to 75% (vs. 65% with lenalidomide alone) and extended median PFS to 59.1 months (vs. 41.6 months) | • High-risk genetics (2025 IMS/IMWG high-risk genetics — del(17p)/TP53, t(4;14) + 1q+, or R2-ISS 3–5 pts), where single-agent lenalidomide is not strong enough to prevent early relapse |
| 4. Single-Agent Daratumumab, Bortezomib, or Oral Ixazomib | NCCN Category 1 (Dara / Bortezomib) or Category 2B (Ixazomib, TOURMALINE-MM3) | • CASSIOPEIA: Daratumumab maintenance cut progression risk by 47% (HR 0.53) vs. observation; • Bortezomib every 2 weeks protects del(17p) / t(4;14) | • Patients who cannot tolerate lenalidomide (due to severe rash, cytopenias, or kidney failure) or who need an all-oral proteasome inhibitor (ixazomib) |
| 5. Non-Transplant Continuous Maintenance (Dara-Rd / Dara-R / Isa-Rd) | NCCN Category 1 (MAIA, CEPHEUS, IMROZ, and IFM2017-03 Trials) | • MAIA (Dara-Rd): 61.9-month median PFS; • CEPHEUS / IMROZ: Stopping bortezomib after Cycle 8 and continuing Dara-Rd or Isa-Rd keeps 63% to 68% progression-free at 4.5 to 5 years | • Non-transplant patients transitioning smoothly from initial induction into long-term steroid-free or low-steroid maintenance |
What This Means for You: If you have standard-risk myeloma and achieved a deep response, a single daily lenalidomide pill (or Dara-R stepping down to lenalidomide after 2 years) is easy and remarkably effective. If you have high-risk genetics, starting 2-drug maintenance early (often around Day +60 to +90 post-transplant) is essential to keep aggressive subclones suppressed.
Data Sources: NCCN Guidelines v2.2027; EHA-EMN 2025 Guidelines; PERSEUS, AURIGA, FORTE, ATLAS, and McCarthy Meta-Analysis.
2. How Long Does Maintenance Last—And Can You Stop After Sustained MRD Negativity?
Historically, patients were told they had to take full maintenance therapy indefinitely until their myeloma progressed. Today, Sustained MRD Negativity (10⁻⁵ to 10⁻⁶) is giving doctors a scientific speedometer to personalize duration:
| Clinical Scenario | What the Latest Trials & Guidelines Show | Recommended Action for You |
|---|---|---|
| 1. Standard Guideline Baseline (Continuous vs. Fixed Duration) | • The STaMINA and DETERMINATION trials showed that continuing lenalidomide until progression achieved higher long-term PFS (79.5% vs. 61% at 5 years) than stopping blindly at 2 or 3 years without checking MRD | • Plan on taking maintenance for at least 2 to 3 years (and continuously if tolerated), unless guided by serial MRD testing with your specialist |
| 2. Stepping Down from 2 Drugs to 1 Drug (The PERSEUS Rule) | • In the PERSEUS trial, patients took daratumumab + lenalidomide for 24 months; those in Complete Response who maintained 10⁻⁵ Sustained MRD Negativity for ≥ 12 months stopped daratumumab and stayed on lenalidomide alone, achieving a 95.3% 4-year PFS | • If you are on 2-drug Dara-R maintenance and remain MRD-negative for ≥ 12 months after completing 2 years of maintenance, ask your doctor about dropping daratumumab shots |
| 3. Stopping All Maintenance in Standard-Risk Patients (MASTER / GEM2014MAIN / MRD2STOP) | • In GEM2014MAIN and MRD2STOP, standard-risk patients who remained MRD-negative (10⁻⁵ or 10⁻⁶) after 2 to 3+ years of maintenance had very low relapse rates after stopping therapy; EHA-EMN 2025 notes that stopping after 3 years of sustained MRD negativity is an emerging option | • Never stop maintenance on your own; if you are standard-risk with 2 to 3+ years of documented Sustained MRD Negativity (10⁻⁶) and significant side effects, discuss an MRD-monitored holiday or clinical trial with your specialist |
| 4. High-Risk Genetics (2025 IMS/IMWG or Double-Hit Myeloma) | • In the MASTER and MRD2STOP trials, patients with ≥ 2 high-risk genetic abnormalities who stopped therapy after reaching MRD negativity experienced high rates of rapid relapse (27%+ within 2 years) | • Do NOT stop maintenance early if you have high-risk genetics; continuous 2-drug maintenance remains your strongest protection against sudden relapse |
What This Means for You: A single negative MRD test at Day +100 is a reason to celebrate, not a reason to quit your pills. However, if you sustain MRD negativity for 1 to 3+ years, modern guidelines (NCCN v2.2027) support shared decision-making to step down from 2 drugs to 1 drug—or, in carefully monitored standard-risk cases, to discuss whether long-term treatment-free surveillance is appropriate.
Data Sources: NCCN Guidelines v2.2027; EHA-EMN 2025 Guidelines; PERSEUS, MASTER, GEM2014MAIN, and MRD2STOP Trials.
3. Managing Long-Term Side Effects: Living Well on Maintenance
Because maintenance therapy lasts for years, small daily annoyances matter. Nearly every maintenance side effect can be resolved without sacrificing your myeloma control:
| Common Long-Term Side Effect | Why It Happens & Warning Thresholds | Proven Medical & Lifestyle Fixes |
|---|---|---|
| 1. Low Blood Counts (Neutropenia or Low Platelets) | Lenalidomide gently suppresses bone marrow production; Grade 3–4 neutropenia (ANC < 1.0 × 10⁹/L or < 1,000/μL) occurs in up to 50% of patients | • Switch from continuous 28-day dosing to 21 days on, 7 days off; • Step down the dose (15 mg → 10 mg → 5 mg daily → 5 mg every other day); • Use occasional G-CSF (filgrastim) shots if needed |
| 2. Chronic Watery Diarrhea (After 6 to 12+ Months) | Long-term lenalidomide causes bile acid malabsorption in the small intestine, triggering sudden post-meal watery stools | • Cut back on greasy, high-fat meals and dairy; • Ask your doctor for a prescription bile-acid binder (colesevelam or cholestyramine) taken with meals—it stops lenalidomide diarrhea far better than loperamide alone |
| 3. Fatigue, Muscle Cramps & Mild Skin Rash | T-cell activation and mild electrolyte shifts from lenalidomide or proteasome inhibitors | • Take lenalidomide at bedtime to sleep through mild fatigue; • Stay well hydrated and check magnesium/potassium levels (or drink tonic water / take magnesium glycinate as approved) for night leg cramps |
| 4. Blood Clot Risk (DVT or Pulmonary Embolism) | Lenalidomide slightly thickens blood-clotting signals, even when taken without steroids | • Continue daily low-dose aspirin (81 to 100 mg) if you are low-risk for clots, or a preventive blood thinner (apixaban or rivaroxaban) if you have prior clots or high risk |
| 5. Infections & Low Normal Antibodies (IgG < 400 mg/dL [< 4.0 g/L]) | Anti-CD38 antibodies (daratumumab) and transplant wipe out normal infection-fighting immunoglobulins and prior vaccine memory | • Stay on daily acyclovir or valacyclovir (shingles prevention); • Complete post-transplant re-vaccinations starting at 3 to 6 months (pneumococcal, flu, COVID-19, recombinant Shingrix); • Receive monthly IVIG infusions if IgG < 400 mg/dL (< 4.0 g/L) with recurrent infections |
| 6. Second Primary Malignancies (SPM) | Post-melphalan lenalidomide carries a small long-term risk (6% to 8% over 5+ years, mostly non-melanoma skin cancers) | • Remember that lenalidomide reduces overall death risk by 25% (survival benefit far outweighs SPM risk); • Wear sunscreen, get an annual dermatology skin check, and stay current on routine colon, breast, or prostate screenings |
Struggling With Unpredictable Diarrhea on Lenalidomide? Ask About Colesevelam
Many patients silently restrict their social lives after a year on lenalidomide because of sudden watery diarrhea, assuming it is an unavoidable chemo side effect. Clinical studies proved that lenalidomide diarrhea is usually caused by unabsorbed bile acids in the gut. Taking a simple cholesterol-type bile-acid binder pill (colesevelam / Welchol or cholestyramine) binds those acids and restores normal bowel habits in the vast majority of patients.
Data Sources: NCCN Guidelines v2.2027 (Supportive Care); EHA-EMN 2025 Guidelines; EBMT Post-ASCT Maintenance Consensus.
Common Pitfalls to Avoid
Pitfall 1: Stopping Maintenance Pills on Your Own Because You "Feel Great and Labs Are Zero"
❌ The Pitfall: Quitting lenalidomide after 6 or 12 months without telling your doctor because your blood M-protein is undetectable and you are tired of taking pills.
✅ The Right Move: Understand that invisible myeloma cells remain suppressed only while the maintenance "security patrol" is on duty. Always discuss side effects or MRD-guided step-down timelines openly with your hematologist rather than stopping abruptly.
Pitfall 2: Using Only Single-Agent Lenalidomide When You Have High-Risk Genetics
❌ The Pitfall: Taking lenalidomide monotherapy after transplant despite having del(17p) / TP53 mutation, t(4;14) + 1q+, or double-hit myeloma.
✅ The Right Move: Meta-analyses show that single-agent lenalidomide alone does not fully overcome high-risk genetics. Ask your specialist for a 2-drug maintenance combination (carfilzomib + lenalidomide, bortezomib + lenalidomide, or daratumumab + lenalidomide).
Pitfall 3: Forgetting to Adjust Your Lenalidomide Dose If Your Kidney Function Changes
❌ The Pitfall: Taking a full 10 mg or 15 mg daily dose of lenalidomide when your creatinine clearance (CrCl or eGFR) drops below 50 to 60 mL/min, causing severe drops in white blood cells and platelets.
✅ The Right Move: Because lenalidomide is cleared through the kidneys, your doctor will match the capsule strength to your kidney numbers (such as 10 mg daily for moderate kidney impairment, 15 mg every other day for severe non-dialysis impairment, or 5 mg daily after dialysis).
Pitfall 4: Skipping Post-Transplant Re-Vaccinations and Shingles Prevention
❌ The Pitfall: Assuming your childhood vaccines or pre-transplant shots still protect you after an autologous stem cell transplant, or stopping acyclovir/valacyclovir while on bortezomib or daratumumab maintenance.
✅ The Right Move: High-dose melphalan erases most of your immune memory. Follow your transplant center's 3-to-24-month killed/inactivated re-vaccination calendar (including the non-live Shingrix shingles vaccine and pneumococcal shots) and keep taking daily antiviral prophylaxis as prescribed.
Summary: Your Quick Decision Guide
Maintenance Therapy Regimens, Step-Down & Side-Effect Care
Select your risk profile or switch inside any card to view NCCN v2.2027 & PERSEUS maintenance rules:
1-Drug vs. 2-Drug Choice
52.8-mo median PFS vs. 23.5 mo; cuts death risk 25%
64.8% achieve sustained MRD negativity (10⁻⁵)
Use if severe rash or kidney impairment occurs
Duration & MRD Step-Down
Drop Dara at 24 mos if sustained 10⁻⁵ MRD- ≥ 12 mos
Requires serial negative tests ≥ 1 year apart
Stopping all drugs is studied in standard-risk trials
Side-Effect Solutions
Bile-acid binder + low-fat diet fixes gut irritation
Add a 7-day rest week or step down 10 mg → 5 mg
Adjust capsule strength to kidney clearance
Key Takeaways & Next Steps
- Maintenance doubles your remission: Staying on tailored maintenance therapy is the proven bridge that turns a deep initial response into 4 to 7+ years of disease-free living.
- Let risk and Sustained MRD guide your intensity: High-risk patients need continuous 2-drug maintenance, while standard-risk patients on 2-drug Dara-R can aim for the PERSEUS step-down to single-pill lenalidomide once they achieve ≥ 12 months of Sustained MRD Negativity after 2 years.
- Speak up early about side effects: Dose step-downs (10 mg to 5 mg), 7-day rest breaks each month, and bile-acid binders (colesevelam) allow almost every patient to live comfortably on maintenance.
Working hand in hand with your oncology team ensures your maintenance plan protects both your remission and your everyday joy.
Next Steps & Related Decision Guides
- Frontline Treatment Roadmap: Reviewing where maintenance fits in the long-term 6-step journey? Read our Treatment Roadmap Guide.
- MRD Testing & Step-Down Rules: Understanding how 10⁻⁵ and 10⁻⁶ sensitivity unlocks safe maintenance de-escalation? Explore our MRD Testing Guide.
- Autologous Transplant Deep-Dive: Navigating stem cell harvest timing and high-dose melphalan recovery? Review our Autologous Transplant Guide.
- High-Risk Genetics Playbook: Managing del(17p), TP53, and tandem maintenance combinations? Check our High-Risk Myeloma Guide.
- Recognizing Relapse Signs: Tracking early biochemical spikes vs. clinical symptoms while on maintenance? See our Recognizing Relapse Signs Guide.
5 Questions to Ask Your Doctor
- One Drug vs. Two Drugs: "Given my baseline FISH genetics and my current response/MRD status, do I need single-agent lenalidomide or a 2-drug maintenance combination (Dara-R, KR, or VR)?"
- Dosing Schedule & Kidney Adjustment: "Should I take my lenalidomide continuously for 28 days or on a 21-days-on / 7-days-off schedule, and is my dose adjusted for my kidney function?"
- Can We Track Sustained MRD to Guide Step-Down?: "If I am on 2-drug Dara-R maintenance and stay MRD-negative for ≥ 12 months after 2 years, can we plan to drop the daratumumab injections?"
- Fixing Diarrhea, Cramps, or Fatigue: "If I develop chronic watery stools or low blood counts months from now, can we try a bile-acid binder (colesevelam) or step down to a 5 mg capsule?"
- Vaccines, Antivirals & Cancer Screening: "When do I start my post-transplant re-vaccination schedule, do I stay on acyclovir and aspirin, and what annual skin or cancer screenings should I schedule?"
References
- National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Multiple Myeloma, Version 2.2027 (2026). Available at: https://www.nccn.org
- Dimopoulos MA, Terpos E, Boccadoro M, et al. EHA-EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma. Nat Rev Clin Oncol. 2025.
- McCarthy PL, Holstein SA, Petrucci MT, et al. Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis. J Clin Oncol. 2017;35(29):3279-3289.
- Sonneveld P, Dimopoulos MA, Boccadoro M, et al. Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma (PERSEUS). N Engl J Med. 2024;390(4):301-313.
- Badros A, Foster L, Anderson LD, et al. Daratumumab plus Lenalidomide Versus Lenalidomide Alone as Maintenance Therapy in Newly Diagnosed Multiple Myeloma After Transplant (AURIGA). Blood. 2025;145(3):300-310.
- Dytfeld D, Wrobel T, Jamroziak K, et al. Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS). Lancet Oncol. 2023;24(2):139-150.
- Derman BA, Major A, Cooperrider J, et al. Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP). Blood Cancer J. 2024;14(1):170.
This clinical decision guide is synthesized from international consensus guidelines and peer-reviewed literature for educational purposes only. It does not substitute for professional medical care. Consult your treating hematology-oncology team regarding diagnostic and treatment decisions.
CMDN Care · Myeloma Companion
Organize your lab reports, follow biomarker trends, and prepare questions for your care team with CMDN’s English-language companion for myeloma patients and caregivers.
Open CMDN CareHow CMDN Care worksSign in with Google or a secure email code.
Lab report OCR
Review results extracted from your reports.
Biomarker trends
Keep follow-up results in one place.
Visit preparation
Bring your questions to your care team.
FAQs
- If my M-protein is zero and I am in Complete Response, why do I still need maintenance pills?
- Even when blood tests and bone marrow biopsies look completely clear, tiny pockets of dormant myeloma cells can hide inside the bones. Maintenance therapy acts like a low-dose security patrol—meta-analyses of over 1,200 patients proved that taking lenalidomide maintenance more than doubles average remission time from 23.5 months to 52.8 months and cuts the risk of death by 25%.
- Can I stop maintenance therapy if my bone marrow MRD test is negative, and how long is it taken?
- Never stop after a single negative MRD test. Under NCCN (v2.2027) and the PERSEUS trial protocol, if you are on 2-drug daratumumab + lenalidomide maintenance for 24 months and maintain Sustained MRD Negativity (10⁻⁵ for ≥ 12 months), you can safely stop the daratumumab shots and continue lenalidomide pills alone. Stopping all maintenance drugs completely is currently studied in trials (after 2 to 3+ years of sustained MRD negativity in standard-risk patients) and requires careful shared decision-making.
- How does my doctor decide between 1 maintenance drug (lenalidomide alone) and 2 maintenance drugs for high-risk disease?
- Your baseline genetics and post-transplant MRD status guide the choice. Standard-risk patients who are MRD-negative do very well on single-agent lenalidomide (10 mg daily). However, if you have high-risk FISH genetics (such as del(17p)/TP53 or t(4;14) + 1q+) or remain MRD-positive after transplant (AURIGA trial), pairing lenalidomide with a second drug (daratumumab, carfilzomib, or bortezomib) is strongly recommended.
- Why does lenalidomide cause watery diarrhea or low counts after several months, and what fixes it?
- Long-term lenalidomide can irritate the small intestine so it stops absorbing normal digestive bile acids—a condition called bile acid malabsorption. Eating a lower-fat diet and asking your doctor for a prescription bile-acid binder (colesevelam or cholestyramine) resolves the diarrhea in most patients, while low blood counts are easily managed by stepping down from 10 mg to 5 mg or using a 21-days-on, 7-days-off schedule.
- Does lenalidomide maintenance increase the risk of a second cancer, and is it still worth taking?
- Yes, taking lenalidomide after high-dose melphalan transplant carries a small increase in second primary malignancies (mostly treatable skin cancers and a small percentage of bone marrow or solid tumors). However, large clinical trials proved that lenalidomide maintenance extends overall survival by more than 2.5 years on average—meaning the life-saving benefit against myeloma relapse far outweighs the small secondary risk.
- How often do I need blood tests and bone marrow biopsies during maintenance?
- Once your maintenance dose is stable, you typically have routine blood and urine myeloma labs checked every 1 to 3 months and a whole-body imaging scan (PET/CT or MRI) once a year. Bone marrow biopsies are only needed once a year if you and your doctor are tracking Sustained MRD Negativity.
Related reading
References used for this guide
- NCCN Clinical Practice Guidelines in Oncology: Multiple Myeloma (Version 2.2027)
- EHA-EMN Evidence-Based Guidelines for Diagnosis, Treatment and Follow-Up of Multiple Myeloma (Nat Rev Clin Oncol)
- Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis (J Clin Oncol)
- PERSEUS Phase 3 Trial: Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone with Dara-R Maintenance (N Engl J Med)
- AURIGA Phase 3 Trial: Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Post-Transplant Maintenance (Blood)
- ATLAS and FORTE Trials: Carfilzomib Plus Lenalidomide Versus Lenalidomide Monotherapy Maintenance (Lancet Oncol)
for their academic support:
for myeloma patients globally